UniFAHS: Rethinking Livestock Health Through Phage Biotechnology

We are excited to announce our investment in UniFAHS, a Southeast Asia-based phage biotechnology company developing natural alternatives to antibiotics in livestock, co-investing alongside leading deeptech and agritech investors. At A2D Ventures, we look for companies tackling structural problems that are easy to overlook but difficult to solve, and UniFAHS sits right at the intersection of food safety, sustainability, and biological innovation where traditional approaches are starting to break.

—-------------------------------------------------

A large agricultural system facing a growing biological constraint

Livestock is one of the largest and most critical industries in Southeast Asia.

Thailand alone is the 4th largest exporter of chicken globally, with billions of birds produced annually and deeply integrated into global food supply chains. 

At the same time, the industry is under increasing pressure.

Antibiotics have long been used to maintain productivity and prevent disease. But over time, this has led to antimicrobial resistance (AMR), now considered one of the most serious global health risks. It is estimated that AMR could cause up to 10 million deaths annually by 2050, surpassing many major diseases.

This creates a structural challenge.

The industry cannot continue operating the same way.But replacing antibiotics at scale is not straightforward.

A system built on antibiotics, now forced to evolve

Today’s livestock system is highly dependent on antibiotics for efficiency.

Removing them without a viable alternative risks reducing productivity, increasing disease outbreaks, and impacting food supply. At the same time, regulators, consumers, and global buyers are pushing for safer and more sustainable practices.

This creates a difficult balance.

Producers need solutions that are:

• effective at scale

• economically viable

• safe for both animals and humans

Very few technologies meet all three.

A biological approach that works with nature, not against it

UniFAHS approaches this problem differently.

Instead of using chemicals, the company uses bacteriophages — naturally occurring viruses that selectively target harmful bacteria without affecting beneficial ones.

This allows for precision.

Their platform combines a proprietary phage library, patented formulation technology, and tailored application models, enabling customized treatment at the farm level. 

The result is a solution that is:

• targeted rather than broad-spectrum

• environmentally safe

• compatible with existing farming systems

In a category dominated by blunt tools, this level of precision matters.

Early validation from industry leaders

What stood out to us was not just the science, but the adoption.

UniFAHS is already working with some of the largest agribusiness players in the region, including CP Group, Cargill, and JAFPA, validating both product-market fit and commercial relevance. 

The company has also demonstrated strong growth, with ~230% CAGR, alongside attractive unit economics with the ability to price at meaningful multiples over cost. 

In biotech, early commercial traction is not common.

Here, it is already visible.

Why we invested

Some technologies feel inevitable, but take time to find the right application.

Phage is one of them.

What UniFAHS is doing is not just introducing a new product. It is enabling the livestock industry to transition away from a dependency that is no longer sustainable.

That shift will take time.

But when it happens, solutions like this do not stay niche.They become standard.

For more information about A2D Ventures, please visit our website.

For more information about UniFAHS, please visit their website.